0001144204-11-030186.txt : 20110516 0001144204-11-030186.hdr.sgml : 20110516 20110516170054 ACCESSION NUMBER: 0001144204-11-030186 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110331 FILED AS OF DATE: 20110516 DATE AS OF CHANGE: 20110516 EFFECTIVENESS DATE: 20110516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 11848157 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v222695_13f-hr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2011 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. May 16, 2011 -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 59 ----------- Form 13F Information Table Entry Value: $2,401,886 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 3-31-2011
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 7,070 4,364,070 SH SOLE 4,364,070 Achillion COM 00448Q201 5,736 802,200 SH SOLE 802,200 Adolor Corp. COM 00724X102 9,726 6,947,343 SH SOLE 6,947,343 Alere Inc. COM 01449J105 45,741 1,168,644 SH SOLE 1,168,644 Alere Inc. PFD Conv PFD CONV 01449J204 202 732 SH SOLE 732 Alkermes COM 01642T108 6,538 504,827 SH SOLE 504,827 Alnylam COM 02043Q107 1,586 165,842 SH SOLE 165,842 Amicus Therapeutics COM 03152W109 8,010 1,129,755 SH SOLE 1,129,755 Anacor Pharmaceuticals COM 32420101 7,183 1,038,038 SH SOLE 1,038,038 Anadys Pharmaceuticals Inc. COM 03252Q408 70 60,509 SH SOLE 60,509 Anthera Pharmaceuticals COM 03674U102 5,400 800,000 SH SOLE 800,000 AP Pharma COM 00202J203 1,578 6,861,818 SH SOLE 6,861,818 Aradigm Corp. COM 038505301 18 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 172,484 6,011,989 SH SOLE 6,011,989 Autoimmune Inc. COM 052776101 - 13,050 SH SOLE 13,050 Auxilium COM 05334D107 156,553 7,291,708 SH SOLE 7,291,708 Avanir Pharmaceuticals COM 05348P401 2,040 500,000 SH SOLE 500,000 Biocryst Pharmaceuticals Inc. COM 09058V103 21,086 5,563,615 SH SOLE 5,563,615 BioDelivery Sciences Intl. Inc. COM 09060J106 8,486 2,403,848 SH SOLE 2,403,848 Biomarin COM 09061G101 9,758 388,310 SH SOLE 388,310 Cadence Pharmaceuticals COM 12738T100 355 38,717 SH SOLE 38,717 Chelsea Therapeutics COM 163428105 4,325 1,114,700 SH SOLE 1,114,700 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 96 22,355 SH SOLE 22,355 Cumberland Pharmaceuticals COM 230770109 533 96,381 SH SOLE 96,381 Depomed COM 249908104 1,839 183,145 SH SOLE 183,145 Exelixis Inc. COM 30161Q104 12,234 1,079,804 SH SOLE 1,079,804 Genomic Health Inc. COM 37244C101 183,731 7,468,742 SH SOLE 7,468,742 GTX Inc. COM 40052B108 4,453 1,732,660 SH SOLE 1,732,660 Halozyme Therapeutics Inc. COM 40637H109 26,462 3,946,559 SH SOLE 3,946,559 Idera Pharmaceuticals Inc. COM 45168K108 761 288,401 SH SOLE 288,401 Incyte Corp. COM 45337C102 175,627 11,080,561 SH SOLE 11,080,561 Infinity Pharmaceuticals Inc. COM 45665G303 628 106,792 SH SOLE 106,792 Inhibitex Inc. COM 45719T103 3,358 927,793 SH SOLE 927,793 Intermune Inc. COM 45884X103 70,152 1,486,586 SH SOLE 1,486,586 Ligand Pharmaceuticals Inc. CLASS B 53220K207 836 83,613 SH SOLE 83,613 Medivation Inc. COM 58501N101 10,867 583,018 SH SOLE 583,018 Micromet COM 59509C105 10,778 1,922,932 SH SOLE 1,922,932 Pharmacyclics Inc. COM 716933106 12,808 2,174,461 SH SOLE 2,174,461 Pharmasset Inc. COM 71715N106 137,859 1,751,476 SH SOLE 1,751,476 Pozen COM 73941U102 617 114,984 SH SOLE 114,984 Salix Pharmaceuticals, Inc. COM 795435106 2,912 83,118 SH SOLE 83,118 Seattle Genetics Inc. COM 812578102 300,238 19,283,142 SH SOLE 19,283,142 Threshold Pharma COM 885807107 5,653 3,670,627 SH SOLE 3,670,627 Trimeris Inc. COM 896263100 8,724 3,475,475 SH SOLE 3,475,475 Via Pharmaceuticals COM 92554T103 6 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 208,195 10,462,071 SH SOLE 10,462,071 Xenoport COM 98411C100 1,859 313,429 SH SOLE 313,429 Xoma Ltd. COM G9825R206 1,117 400,400 SH SOLE 400,400 YM Biosciences COM 984238105 24,027 9,101,282 SH SOLE 9,101,282 Ziopharm Oncology Inc. COM 98973P101 5,561 889,707 SH SOLE 889,707 Alere Inc. Conv. Notes 3% 5/15/16 CONV BONDS 01449JAA3 6,765 6,000,000 PRN SOLE 6,000,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 3 3,000 PRN SOLE 3,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 8,748 6,410,000 PRN SOLE 6,410,000 Dendreon Corp. Notes 2.875% 1/15/16 CONV BONDS 24823QAC1 6,360 6,000,000 PRN SOLE 6,000,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 7,183 4,500,000 PRN SOLE 4,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 320,800 160,000,000 PRN SOLE 160,000,000 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 55,150 20,900,000 PRN SOLE 20,900,000 Salix 144A 5.5% 8/15/28 CONV BONDS 795435AB2 170,658 44,500,000 PRN SOLE 44,500,000 Salix 2.75% 5/15/15 CONV BONDS 795435AC0 140,343 130,400,000 PRN SOLE 130,400,000